Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Valeria A. S. De Melo"'
Autor:
Richard E. Clark, Jane F. Apperley, Alistair Reid, Philippa C. May, Mustafa Daghistani, Letizia Foroni, David Marin, Lihui Wang, Jamshid S. Khorashad, Gareth Gerrard, Christos Paliompeis, Dragana Milojkovic, John M. Goldman, Valeria A. S. De Melo
Publikováno v:
Blood. 116:6014-6017
Activation of the EVI-1 oncogene has been reported in acute myeloid leukemia, chronic myeloid leukemia (CML) in blast crisis, and less commonly, in chronic-phase CML patients. We screened an unselected cohort of 75 chronic-phase CML patients who had
Autor:
Donald Macdonald, Richard Szydlo, Simon D. Wagner, Alistair Reid, Avni Sheth, Valeria A. S. De Melo
Publikováno v:
Cancer Genetics and Cytogenetics. 194:48-52
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. Certain chromosomal translocations are associated with clinical outcome, but it is likely that there are both tumor suppressor genes and oncogenes that cooperate with the primary trans
Autor:
Ming Hu, Alistair Reid, Valeria A. S. De Melo, Amin Rahemtulla, Anastasios Karadimitris, Emmanouil Spanoudakis, Saad Abdalla, Evangelos Terpos, Ioannis Kotsianidis, Kikkeri N. Naresh
Publikováno v:
Blood. 113:2498-2507
Down-regulation of conventional human leukocyte antigen (HLA) class I and II molecules from the surface of tumor cells is an important mechanism for tumor immune evasion, survival, and progression. Whether CD1d, a nonconventional, glycolipid-presenti
Autor:
Kikkeri N. Naresh, Alistair Reid, K. Elderfield, Valeria A. S. De Melo, Ian Clark, Jane F. Apperley, David Marin
Publikováno v:
Leukemia Research. 33:418-425
We identified different phenotypic subsets among 62 cases of chronic myeloid leukemia (CML) in blast crisis (BC) (26% B-lymphoblastic, and 74% various myeloblastic subsets) on bone marrow trephines and correlated the blast-phenotype with cytogenetics
Autor:
Jamshid S. Khorashad, Eduardo Olavarria, John M. Goldman, Alistair Reid, Valeria A. S. De Melo, Jane F. Apperley, Jaspal Kaeda, Sara Ghorashian, Anna Babb, Puja K. Mehta, David Marin, Mona Anand, Hugues de Lavallade, Dragana Milojkovic
Publikováno v:
Blood. 111:2378-2381
We sought kinase domain (KD) mutations at the start of treatment with dasatinib in 46 chronic myeloid leukemia (CML) patients resistant to or intolerant of imatinib. We identified BCR-ABL mutant subclones in 12 (26%) cases and used pyrosequencing to
Autor:
Anastasios Karadimitris, Alistair Reid, Evdoxia Hatjiharissi, Michael P. H. Stumpf, Kikkeri N. Naresh, Chris P. Barnes, Gillian Cowan, Philippa C. May, Valeria A. S. De Melo, Amin Rahemtulla, Irene Roberts, Helen Doolittle, Heather A. Harrington, Meletios A. Dimopoulos, Letizia Foroni, Maria Papaioannou, Evangelos Terpos, Aristeidis Chaidos, Helen Yarranton, Saad Abdalla
Publikováno v:
Blood. 121(2)
Abstract 2909 Unlike the established role of acquired genetic events and bone marrow microenviroment in the pathogenesis of multiple myeloma (MM), the phenotype and function of cells enriched in tumor-propagating activity and their relationship to th
Autor:
Jane F. Apperley, Elisabeth P. Nacheva, David Marin, Valeria A. S. De Melo, Dragana Milojkovic, Alistair Reid
Publikováno v:
Cancer genetics and cytogenetics. 182(2)
Deletions at the t(9;22) breakpoint regions, found in 15% of chronic myeloid leukemia patients (CML) with an overt Philadelphia (Ph) translocation, are associated with an adverse disease prognosis in patients receiving interferon-alpha therapy. The i
Autor:
Dragana Milojkovic, Valeria A. S. De Melo, David Marin, Jane F. Apperley, Jamshid S. Khorashad, John M. Goldman, Alistair Reid
Publikováno v:
Blood. 110(8)
To the editor: Descriptions of chromosomally abnormal Philadelphia-negative (Ph−) clones in chronic myeloid leukemia (CML) patients treated with chemotherapy,[1][1] interferon-alpha,[2][2] and, most recently, imatinib[3][3],[4][4] suggest that such
Autor:
Sarah, Marktel, David, Marin, Nicola, Foot, Richard, Szydlo, Marco, Bua, Anastasios, Karadimitris, Valeria A S, De Melo, Paul, Kotzampaltiris, Francesco, Dazzi, Amin, Rahemtulla, Eduardo, Olavarria, Jane F, Apperley, John M, Goldman
Publikováno v:
Haematologica. 88(3)
The acquisition of additional cytogenetic changes (clonal evolution, CE) during treatment of chronic myeloid leukemia (CML) with imatinib mesylate is currently regarded as an index of increasing resistance to imatinib. Therefore, to investigate wheth
Autor:
Valeria A. S. De Melo, Jane F. Apperley, Alistair Reid, David Marin, John M. Goldman, Dan Brudzevsky, Jamshid S. Khorashad, Heike Fiegler, Letizia Foroni, Gareth Gerrard
Publikováno v:
Blood. 112:3113-3113
Despite the presence of a consistent genetic abnormality, CML patients display considerable clinical heterogeneity, the basis of which is poorly understood. We therefore used a novel ultra-high-resolution genomic screening assay to search for additio